Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development	$ 2,235,542	$ 1,670,862
General and administrative	1,617,924	531,598
Total operating expenses	3,853,466	2,202,460
Loss from operations	(3,853,466)	(2,202,460)
Other income:
Interest income	56,268	19,645
Total other income	56,268	19,645
Net loss	(3,797,198)	(2,182,815)
Preferred stock dividend		(221,278)
Net loss applicable to common stockholders	(3,797,198)	(2,404,093)
Other comprehensive income (loss):
Foreign currency translation adjustments	(20,283)
Comprehensive loss	$ (3,817,481)	$ (2,182,815)
Net loss applicable to common stockholders per share, basic and diluted	$ (0.20)	$ (0.55)
Weighted average common shares outstanding, basic and diluted	19,008,611	4,400,000